NCT06492863View on ClinicalTrials.gov

Gene Therapy(FT-003) for Wet AMD

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

October 15, 2024

Study Completion Date

October 15, 2028

Conditions
Neovascular Age-related Macular Degeneration
Interventions
GENETIC

FT-003

Administered via intraocular injection.

Trial Locations (1)

300392

RECRUITING

Tianjin Medical University Eye Hospital, Tianjin

Sponsors
All Listed Sponsors
collaborator

Tianjin Medical University Eye Hospital

OTHER

collaborator

The First Affiliated Hospital of Soochow University

OTHER

collaborator

Peking Union Medical College Hospital

OTHER

collaborator

Beijing Hospital

OTHER_GOV

lead

Frontera Therapeutics

INDUSTRY

NCT06492863 - Gene Therapy(FT-003) for Wet AMD | Biotech Hunter | Biotech Hunter